Evidence-based diagnostic algorithm for glioma: Analysis of the results of pathology panel review and molecular parameters of EORTC 26951 and 26882 trials

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1943-1950

  Kros, Johan M ^a   Huizer, Karin ^a   Hernández Laín, Aurelio ^b   Marucci, Gianluca ^d   Michotte, Alex ^f   Pollo, Bianca ^e   Rushing, Elisabeth J ^h   Ribalta, Teresa ^c   French, Pim ^a   Jaminé, David ^g   Bekka, Nawal ^g   Lacombe, Denis ^g   Van Den Bent, Martin J ^a   Gorlia, Thierry ^g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g EORTC DATA CENTER   (Belgium)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; DNA LIGASE; DNA METHYLTRANSFERASE; EGFR PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ASTROCYTOMA; ASTROCYTOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 7; CHROMOSOME GAIN; CHROMOSOME LOSS; CLASSIFICATION ALGORITHM; CLINICAL TRIAL (TOPIC); CONSENSUS; CONTROLLED STUDY; EPENDYMOMA; EVIDENCE BASED PRACTICE; GENE AMPLIFICATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROSCOPY; MITOSIS INDEX; MOLECULAR DIAGNOSIS; MORPHOLOGY; NEUROPATHOLOGY; NUMERICAL CHROMOSOME ABERRATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR NECROSIS; VALIDATION STUDY; ADULT; AGED; ALGORITHM; BRAIN TUMOR; CHEMISTRY; CHROMOSOME DELETION; COMPUTER INTERFACE; DNA METHYLATION; EVIDENCE BASED MEDICINE; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ALGORITHMS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 7; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EVIDENCE-BASED MEDICINE; FEMALE; GENE AMPLIFICATION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MICROSCOPY; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; USER-COMPUTER INTERFACE;

EID: 84937622404     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0166     Document Type: Article

References (37)

1. Weller M, Berger H, Hartmann C, et al: Combined 1p/19q loss in oligodendroglial tumors: Predictive or prognostic biomarker? Clin Cancer Res 13:6933-6937, 2007
2. Kouwenhoven MC, Gorlia T, Kros JM, et al: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 11:737-746, 2009
3. Vogelbaum MA, Berkey B, Peereboom D, et al: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 11:167-175, 2009
4. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
5. Lecavalier-Barsoum M, Quon H, Abdulkarim B: Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 5:CD007104, 2014
6. Roth P, Wick W, Weller M: Anaplastic oligodendroglioma: A new treatment paradigm and current controversies. Curr Treat Options Oncol 14:505-513, 2013
7. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
8. van den Bent MJ, Dubbink HJ, Sanson M, et al: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886, 2009
9. van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al: MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic oligodendrogliomas and oligoastrocytomas: A report from EORTC study 26951. Clin Cancer Res 19:5513-5522, 2013
10. Labussière M, Di Stefano AL, Gleize V, et al: TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111:2024-2032, 2014
11. Mellinghoff IK, Cloughesy TF, Mischel PS: PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13:378-381, 2007
12. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024, 2005
13. Brennan CW, Verhaak RG, McKenna A, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
14. Louis DN, Perry A, Burger P, et al: International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24:429-435, 2014
15. Coons SW, Pearl DK: Mitosis identification in diffuse gliomas: Implications for tumor grading. Cancer 82:1550-1555, 1998
16. Coons SW, Johnson PC, Scheithauer BW, et al: Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393, 1997
17. Kros JM, Gorlia T, Kouwenhoven MC, et al: Panel review of anaplastic oligodendroglioma from European Organisation For Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545-551, 2007
18. Giannini C, Scheithauer BW, Weaver AL, et al: Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248-262, 2001
19. Hegi ME, Janzer RC, Lambiv WL, et al: Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: Central pathology review of the EORTC-26981/NCIC-CE. 3 trial. Acta Neuropathol 123:841-852, 2012
20. Hildebrand J, Gorlia T, Kros JM, et al: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 44:1210-1216, 2008
21. van den Bent MJ, Brandes AA, Taphoorn MJ, et al: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344-350, 2013
22. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006
23. Kleihues P, Louis D, Wiestler O, et al: WHO Classification of Tumours of the Central Nervous System (ed 4). Lyon, France, International Agency for Research on Cancer, 2007
24. Gravendeel LA, Kloosterhof NK, Bralten LB, et al: Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat 31:E1186-E1199, 2010
25. Giannini C, Burger PC, Berkey BA, et al: Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group trial 9402. Brain Pathol 18:360-369, 2008
26. Sahm F, Reuss D, Koelsche C, et al: Farewell to oligoastrocytoma: In situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551-559, 2014
27. Wiestler B, Capper D, Holland-Letz T, et al: ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443-451, 2013
28. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69:9065-9072, 2009
29. van den Bent MJ, Gravendeel LA, Gorlia T, et al: A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: A report from EORTC study 26951. Clin Cancer Res 17:7148-7155, 2011
30. Wick W, Meisner C, Hentschel B, et al: Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515-1522, 2013
31. Wiestler B, Capper D, Sill M, et al: Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561-571, 2014
32. van den Bent MJ, Hartmann C, Preusser M, et al: Interlaboratory comparison of IDH mutation detection. J Neurooncol 112:173-178, 2013
33. Berghoff AS, Stefanits H, Woehrer A, et al: Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin Neuropathol 32:148-158, 2013
34. Preusser M, Wöhrer A, Stary S, et al: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70:715-723, 2011
35. Woehrer A, Sander P, Haberler C, et al: FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: Procedures and protocols for neuropathological practice - A publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol 30:47-55, 2011
36. Preusser M, Elezi L, Hainfellner JA: Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 27:388-390, 2008
37. Royds JA, Al Nadaf S, Wiles AK, et al: The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One 6:e26737, 2011